TABLE 2.
Clinical characteristics during Dmab administration.
| Number of doses | |
| Median (IQR) | 12.0 (6.0–24.0) |
| Mean (min‐max) | 14.5 (1–48) |
| Duration of Denosumab in months | |
| Median (IQR) | 12.4 (5.1–23.7) |
| Mean (min‐max) | 10.25 (1–125) |
| Dental extraction | |
| Yes n (%) | 53 (6.8) |
| No n (%) | 727 (93.2) |
| Dental treatment | |
| Yes n (%) | 138 (17.7) |
| No n (%) | 642 (82.3) |
| Antiangiogenic (AA) therapy (**) | |
| Yes n (%) | 15 (1.9) |
| No n (%) | 765 (98.1) |
| Hormone therapy | |
| Yes n (%) | 426 (54.6) |
| No n (%) | 354 (45.4) |
| Chemotherapy | |
| Yes n (%) | 351 (45.0) |
| No n (%) | 429 (55.0) |
| Corticosteroids | |
| Yes n (%) | 214 (27.4) |
| No n (%) | 566 (72.6) |
| Anemia | |
| Yes n (%) | 121 (15.5) |
| No n (%) | 659 (84.5) |
Note: (**) started during Dmab treatment.
Abbreviation: IQR, interquartile range.